| Also known as |
OPC-14597, OPC-31 |
| Blood pressure |
Can cause orthostatic hypotension |
| Chemical name |
7-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one |
| Dosage (medical) |
Typically starts at 10-15 mg once daily for schizophrenia, 2-15 mg once daily for bipolar disorder |
| Dosage (sports) |
Not applicable |
| Effects |
Antipsychotic, mood stabilization, reducing symptoms of schizophrenia and bipolar disorder |
| Formula |
C23H27Cl2N3O2 |
| Half-life |
Approximately 75 hours |
| Hepatotoxicity |
Low |
| Lab Test |
Monitoring blood levels is not typically required, but lipid profiles, blood glucose, and weight should be monitored |
| Main action |
Dopamine D2 and serotonin 5-HT1A receptor partial agonist |
| Raw Material |
Aripiprazol |
| Side effects |
Anxiety, insomnia, nausea, vomiting, blurred vision, somnolence, restlessness, tremor |
| Storage conditions |
Store at room temperature, 15-30В°C (59-86В°F) |
| Substance class |
Atypical antipsychotic |
| Trade name |
Abilify, Aripiprex |
| Use in sports |
None |
| Water Retention |
Minimal |
| Manufacturer |
Bristol - Myers Squibb |
| Packing |
28 tabs (5 mg/tab) |
